Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

Phase 2

Completed

Conditions: Esophageal Cancer

First Posted Date: 2004-04-21

Last Posted Date: 2013-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00016900

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-04-19

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005625

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-04-12

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005040

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-12

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00004238

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers

Phase 2

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2004-04-09

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003754

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-04-08

Last Posted Date: 2013-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00081133

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-04-08

Last Posted Date: 2013-07-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00081172

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-08

Last Posted Date: 2013-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00081107

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Breast Cancer
Ovarian Cancer
Prostate Cancer
Bladder Cancer
Kidney Cancer
Colorectal Cancer
Lung Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Esophageal Cancer
Head and Neck Cancer

First Posted Date: 2004-04-06

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 57

Registration Number: NCT00003103

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-04-05

Last Posted Date: 2013-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00022256

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy